Back

WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model

Elangovan, A.; Bossart, E. A.; Basudan, A.; Tasdemir, N.; Shah, O. S.; Ding, K.; Meier, C.; Heim, T.; Neumann, C.; Attaran, S.; Brown, L.; Hooda, J.; Miller, L.; Liu, T.; Puhalla, S. L.; Gurda, G.; Lucas, P. C.; McAuliffe, P. F.; Atkinson, J. M.; Lee, A. V.; Oesterreich, S.

2023-09-17 cancer biology
10.1101/2023.09.15.558023 bioRxiv
Show abstract

Breast cancer is categorized by the molecular and histologic presentation of the tumor, with the major histologic subtypes being No Special Type (NST) and Invasive Lobular Carcinoma (ILC). ILC are characterized by growth in a single file discohesive manner with stromal infiltration attributed to their hallmark pathognomonic loss of E-cadherin (CDH1). Few ILC cell line models are available to researchers. Here we report the successful establishment and characterization of a novel ILC cell line, WCRC-25, from a metastatic pleural effusion from a postmenopausal Caucasian woman with metastatic ILC. WCRC-25 is an ER-negative luminal epithelial ILC cell line with both luminal and Her2-like features. It exhibits anchorage independent growth and haptotactic migration towards Collagen I. Sequencing revealed a CDH1 Q706* truncating mutation, together with mutations in FOXA1, CTCF, BRCA2 and TP53, which were also seen in a series of metastatic lesions from the patient. Copy number analyses revealed amplification and deletion of genes frequently altered in ILC while optical genome mapping revealed novel structural rearrangements. RNA-seq analysis comparing the primary tumor, metastases and the cell line revealed signatures for cell cycle progression and receptor tyrosine kinase signaling. To assess targetability, we treated WCRC-25 with AZD5363 and Alpelisib confirming WCRC-25 as susceptible to PI3K/AKT signaling inhibition as predicted by our RNA sequencing analysis. In conclusion, we report WCRC-25 as a novel ILC cell line with promise as a valuable research tool to advance our understanding of ILC and its therapeutic vulnerabilities. Financial supportThe work was in part supported by a Susan G Komen Leadership Grant to SO (SAC160073) and NCI R01 CA252378 (SO/AVL). AVL and SO are Komen Scholars, Hillman Foundation Fellows and supported by BCRF. This project used the UPMC Hillman Cancer Center and Tissue and Research Pathology/Pitt Biospecimen Core shared resource which is supported in part by award P30CA047904. This research was also supported in part by the University of Pittsburgh Center for Research Computing, RRID:SCR_022735, through the resources provided. Specifically, this work used the HTC cluster, which is supported by NIH award number S10OD028483. Finally, partial support was provided by the Magee-Womens Research Institute and Foundation, The Shear Family Foundation, and The Metastatic Breast Cancer Network.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Cancer Research Communications
51 papers in training set
Top 0.1%
11.8%
2
Cancers
213 papers in training set
Top 0.4%
9.7%
3
Molecular Cancer Research
49 papers in training set
Top 0.1%
9.6%
4
Breast Cancer Research
36 papers in training set
Top 0.1%
7.8%
5
Oncogene
85 papers in training set
Top 0.3%
5.4%
6
Frontiers in Oncology
103 papers in training set
Top 0.7%
5.1%
7
PLOS ONE
5266 papers in training set
Top 33%
4.3%
50% of probability mass above
8
Translational Oncology
21 papers in training set
Top 0.2%
3.2%
9
Cancer Research
130 papers in training set
Top 1%
3.2%
10
BMC Cancer
67 papers in training set
Top 0.7%
2.8%
11
Clinical Cancer Research
64 papers in training set
Top 0.9%
2.1%
12
npj Breast Cancer
23 papers in training set
Top 0.2%
2.1%
13
Cancer Medicine
26 papers in training set
Top 0.5%
1.9%
14
International Journal of Cancer
49 papers in training set
Top 0.6%
1.7%
15
The Journal of Pathology
26 papers in training set
Top 0.4%
1.7%
16
Molecular Oncology
55 papers in training set
Top 0.7%
1.7%
17
Nature Communications
5641 papers in training set
Top 47%
1.5%
18
British Journal of Cancer
49 papers in training set
Top 1%
1.3%
19
The American Journal of Pathology
32 papers in training set
Top 0.5%
1.1%
20
JCI Insight
277 papers in training set
Top 6%
1.1%
21
eLife
5828 papers in training set
Top 62%
1.0%
22
Scientific Reports
3612 papers in training set
Top 72%
0.9%
23
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 42%
0.8%
24
Journal of Biological Chemistry
690 papers in training set
Top 9%
0.8%
25
npj Precision Oncology
53 papers in training set
Top 2%
0.8%
26
Neoplasia
23 papers in training set
Top 0.8%
0.8%
27
Modern Pathology
22 papers in training set
Top 0.4%
0.8%
28
Cancer Letters
35 papers in training set
Top 1%
0.8%
29
Science Advances
1243 papers in training set
Top 33%
0.6%
30
Laboratory Investigation
13 papers in training set
Top 0.3%
0.6%